- Home
- AG vs MYGN Comparison
AG vs MYGN Comparison
Compare AG & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AG | MYGN |
|---|---|---|
| Founded | 1979 | 1991 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 481.6M |
| IPO Year | 2004 | 1996 |
Fundamental Metrics
Financial Performance| Metric | AG | MYGN |
|---|---|---|
| Price | $20.81 | $4.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $21.92 | $7.64 |
| AVG Volume (30 Days) | ★ 18.3M | 1.8M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $13.75 | $7.19 |
| Revenue Next Year | $26.43 | $5.64 |
| P/E Ratio | $143.01 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $5.19 | $3.76 |
| 52 Week High | $32.00 | $9.48 |
Technical Indicators
Market Signals| Indicator | AG | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 44.59 |
| Support Level | $20.21 | $4.24 |
| Resistance Level | $27.90 | $5.69 |
| Average True Range (ATR) | 1.33 | 0.32 |
| MACD | -0.71 | 0.00 |
| Stochastic Oscillator | 30.07 | 32.04 |
Price Performance
Historical ComparisonAbout AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.